RFK Jr. May Reverse a Peptide Ban He Calls “Illegal.” Former FDA Officials Say He Mischaracterized Their Work.

The agency’s 2023 decision to place 19 peptides on the “unsafe” list was supported by numerous documented safety concerns, ...
Regulatory Affairs Professionals Society

This Week at FDA: Makary reflects on first year, FDA working to lift peptide restrictions, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
Becker's Hospital Review

FDA issues new guidance on compounded GLP-1 production

FDA issues guidance compounded GLP-1 production limits, restricting pharmacies to compound only during active shortages to ...
Marijuana Moment

New FDA Enforcement Memo Clears Way For Hemp CBD Product Coverage Under New Medicare Plan

The Food and Drug Administration (FDA) has issued guidance making clear that it does not intend to interfere with ...
Blockonomi

FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks

Cannabis stocks surged with Tilray, Canopy Growth, and Curaleaf posting major gains after FDA announced it will ease CBD ...
Biometric Update

IKE Tech moves to commercialize age gated vapes amid FDA regulatory shift

The U.S. Food and Drug Administration is reluctant to greenlight flavored vapes, due to concerns that they could make ...
MobiHealthNews

Should mHealth companies want FDA regulation?

(I would like to thank Dr. Deepak Ayyagari of Sharp Laboratories of America and Dane Stout of the Anson Group for their comments on a draft. The views expressed, right or wrong, are only the author’s ...
Regulatory Affairs Professionals Society

FDA issues warning letters for false advertising, CGMP violations, and more

The US Food and Drug Administration (FDA) has warned an oncology drug company for repeatedly overstating the efficacy of its drug in advertisements while failing to adequately disclose the associated ...